IMMU:NSD-Immunomedics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.94

Change

0.00 (0.00)%

Market Cap

USD 20.31B

Volume

0.24M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

Company Website : http://www.immunomedics.com

Address : 300 The American Road, Morris Plains, NJ, United States, 07950

Employees : 366

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.90

52 Week High : 87.64

Short Ratio : 3.15

52 Week Low : 8.80

Shorted Shares : 23,599,028

200 Day Moving Average : 47.04

Shorted Shares Previous Month : 26,647,552

50 Day Moving Average : 80.77

Shares Held By Insiders : 1.37%

Short Percentage : 8.00%

Shares Held by Institutions : 81.31%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals, Inc

-15.48 (-2.66%)

 USD61.98B 22.47 17.37
VRTX Vertex Pharmaceuticals Incorpo..

-3.85 (-1.81%)

 USD55.27B 26.75 20.98
SGEN Seagen Inc

-2.07 (-1.05%)

 USD34.26B N/A N/A
MRNA Moderna, Inc

-4.93 (-6.98%)

 USD27.89B N/A N/A
BGNE BeiGene, Ltd

-2.29 (-0.76%)

 USD27.13B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-5.15 (-4.29%)

 USD26.30B 32.43 29.34
RPRX Royalty Pharma plc

-1.75 (-4.62%)

 USD22.99B 33.55 9.19
GMAB Genmab A/S

-1.30 (-3.72%)

 USD22.92B 25.74 2.86
BNTX BioNTech SE

-6.41 (-7.64%)

 USD19.78B -99,999.99 N/A
INCY Incyte Corporation

-1.36 (-1.54%)

 USD19.32B 47.64 35.20

ETFs Containing IMMU

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

-1.00 (-2.01%)

 USD0.03B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.04 %

-5.53 (-9.01%)

 USD0.39B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.15 %

-4.79 (-2.83%)

 USD0.87B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.10 %

-3.93 (-3.08%)

 USD2.40B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

-3.23 (-2.75%)

 USD5.24B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-1.36 (-2.68%)

 USD0.10B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.08 %

-8.76 (-2.72%)

 USD0.87B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.08 %

-7.23 (-2.96%)

 USD2.43B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.40 %

-0.11 (-1.53%)

 USD1.46B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.77% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.77% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -43.52% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.52% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 198.83% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 198.83% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 106.15% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.15% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 116.03% N/A N/A 8% F
Risk Adjusted Return 91.49% N/A N/A 90% A-
Market Capitalization 20.31B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.23 N/A N/A N/A N/A
Price / Cash Flow Ratio -91.30 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -100.04% N/A N/A N/A N/A
Return on Invested Capital -80.14% N/A N/A N/A N/A
Return on Assets -25.16% N/A N/A N/A N/A
Debt to Equity Ratio 96.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.15 N/A N/A N/A N/A
Short Percent 8.66% N/A N/A N/A N/A
Beta 2.90 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.